Trial Profile
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Apr 2024
Price :
$35
*
At a glance
- Drugs Ozanimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms DAYBREAK
- Sponsors Celgene Corporation; Receptos
- 02 Mar 2024 Results of final analysis reporting long-term safety and efficacy of extended ozanimod exposure in patients with relapsing multiple sclerosis presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024
- 02 Mar 2024 Updated findings from the Phase 3 SUNBEAM and DAYBREAK Extension Trials presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024
- 02 Mar 2024 Results assessing the risk of rebound after ozanimod discontinuation during the this trial, presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024.